Devin F. Brecheen, PA

Devin Brecheen practices at Texas Oncology PA in Longview, Texas.

Devin Brecheen's NPI, 1447534854, was assigned on October 4, 2011.

Devin Brecheen's primary practice is Texas Oncology PA, at 1400 N 4th St, Longview, TX 75601 in Gregg County. The practice phone is (972) 997-8000.

Devin Brecheen's primary practice is Texas Oncology PA in Longview, Texas. Devin Brecheen is also affiliated with CHRISTUS Good Shepherd Medical Center - Longview. The medical group on file is Texas Oncology. Dmand AI also links Devin Brecheen to 1 more hospital, 2 medical groups and 1 group practice or clinic, each named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Devin Brecheen practices, 3 sites in all. Vendor and product names are available with a free account.

Physician assistant is Devin Brecheen's primary specialty in the NPI Registry, under taxonomy code 363A00000X. Devin Brecheen is board certified in certified physician assistant by the National Commission on Certification of Physician Assistants (NCCPA). Devin Brecheen has a license on file in Texas.

Dmand AI lists osteoporosis, tobacco use and yeast infection among the conditions Devin Brecheen treats.

CMS data shows 3,641 Medicare services from Devin Brecheen across 20 procedure codes in 2024, for 366 Medicare patients. Medicare paid $80,871 for them.

CMS counts 366 Medicare patients who saw Devin Brecheen in 2024. The largest group is 65 to 74, with 169 patients. 74% of them have high blood pressure, and 68% have high cholesterol. 7% are also on Medicaid. Their average risk score is 1.96, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Devin Brecheen's median patient age at 73, with 55% women.

In 2024, Devin Brecheen wrote 642 Medicare Part D claims for 146 patients. 87% of them were for generic drugs. CMS names the drug for 382 of them, across 13 drugs with 11 or more claims each, at $42,755 in total drug cost.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 85 out of 100 for Devin Brecheen for performance year 2024, reported through an alternative payment model (APM). Devin Brecheen accepts Medicare assignment, so Medicare's approved amount is taken as full payment. CMS lists Devin Brecheen as offering telehealth.

CMS Open Payments shows 100 general payments to Devin Brecheen from 24 drug and device companies from 2024 to 2025. Food and beverage make up the largest share, 91% of the total. Abbvie Inc. paid the most, $321.